Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer

NCT06770439 is registered in ClinicalTrials.gov with Zhejiang University as lead sponsor.

NCT NCT06770439
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06770439 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer
Lead sponsor
Zhejiang University
Phase
Phase 2
Overall status
Recruiting
Start date
April 18, 2025
Completion date
January 31, 2028
Enrollment
64 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced pancreatic cancers